Alpha Cognition Inc
ACOG
Rang in aandelen
#20011
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aandeelprijs
$8.63
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$134.04M
Verandering (1 dag)
0.23%
Verandering (1 jaar)
71.57%
Land
US
Handel Alpha Cognition Inc (ACOG)
Categorie
Healthcare
Koersgeschiedenis voor Alpha Cognition Inc (ACOG)
Hoogste slotkoers: $5.46 op 2024-12-01
Laagste slotkoers: $18.75 op 2021-06-01
Laagste slotkoers: $18.75 op 2021-06-01
Koersgeschiedenis van Alpha Cognition Inc van 2021 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2024 | -51.49% |
| 2023 | 87.35% |
| 2022 | -73.46% |
| 2021 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
